Aviragen Therapeutics, Inc.

As of February 13, 2018, Aviragen Therapeutics, Inc. was acquired by Vaxart, Inc., in a reverse merger transaction. Aviragen Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect patients worldwide. Its product candidates that are in phase II clinical stage development include BTA074, an antiviral treatment for condyloma caused by human papillomavirus types 6 and 11; Vapendavir, a potent antiviral capsid binder for human rhinovirus upper respiratory infections in moderate-to-severe asthmatics; and BTA585, an oral fusion protein inhibitor for the treatment and prevention of respiratory syncytial virus (RSV) infections. The company also has a preclinical RSV non-fusion inhibitor program. It has a research and license agreement with GlaxoSmithKline for the development and commercialization of zanamivir, a neuraminidase inhibitor (NI) to prevent and treat influenza; and collaboration and license agreement with Daiichi-Sankyo for the development of Laninamivir octanoate, an NI for the treatment of influenza. The company was formerly known as Biota Pharmaceuticals, Inc. and changed its name to Aviragen Therapeutics, Inc. in April 2016 to reflect the strategic shift from the organization’s prior focus on drug discovery and early-stage licensing to clinical development of next generation direct-acting antivirals to treat infections. Aviragen Therapeutics, Inc. is headquartered in Alpharetta, Georgia.